Myriad Blog

Announcing Myriad myRisk® Buccal Saliva!

myrisk-buccal-banner

The Myriad myRisk® hereditary cancer panel is now available for buccal saliva samples. Myriad developed and validated a buccal saliva collection and DNA extraction method for full sequencing DNA analysis which provides results identical to blood-based clinical testing. Buccal saliva sample collections will help to improve testing accessibility as hereditary cancer testing becomes increasingly important to provide optimal and individualized patient care. Myriad myRisk® provides information on 25 genes associated with 8 important cancer sites to help you identify patients at a high risk for cancer. Get the most accurate and comprehensive hereditary cancer panel test with clinically actionable results with Myriad myRisk.

  • Myriad myRisk identifies up to 104.5% more mutations than single-syndrome testing, providing a more comprehensive hereditary cancer risk assessment.1,2,3 Rapid turnaround-time of 14-21 days for test results.
  • The Myriad myRisk Management Tool provides a summary of available medical society guidelines to help you optimize your patients’ medical management.
  • Myriad’s commitment to patients and their families is demonstrated with Myriad’s industry-leading variant classification program, myVision™. myVision is the most advanced approach to the classification and reclassification of variants of uncertain significance.

Be confident in knowing your patients’ comprehensive cancer risks with the Myriad myRisk Hereditary Cancer Panel


References:

  1. Prevalence of Gene Mutations Among Hereditary Breast and Ovarian Cancer Patients Using a 25 Gene Panel, Nadine Tung et. al. Presented at ACMG in March 2014
  2. Multi-gene panel testing in patients suspected to have Lynch syndrome, Matthew B. Yurgelun et. al. Presented at ASCO June 2014
  3. Spectrum of Mutations Identified in a 25-gene Hereditary Cancer Panel for Patients with Breast Cancer, Lavania Sharma et. al. Presented at SABCS December 2014

Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad myRisk Hereditary Cancer, the Myriad myRisk Hereditary Cancer logo, Myriad myPath Melanoma, the Myriad myPath Melanoma logo, Myriad myPlan Lung Cancer, the Myriad myPlan Lung Cancer logo, BRACAnalysis, the BRACAnalysis logo, COLARIS, the COLARIS logo, COLARIS AP, the COLARIS AP logo, MELARIS, the MELARIS logo, PANEXIA, the PANEXIA logo, Prolaris, the Prolaris logo, ResultsNow, the ResultsNow logo, Myriad Promise, and the Myriad Promise logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.